[{"from": "human", "value": "Describe this molecule. [C][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C@@H1][C@H1][Branch2][Branch1][#Branch2][C][=Branch1][C][=O][N][Ring1][Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][N][C][=Branch1][C][=O][C][C][C][C][C][C][C][C][C][C][C][=Branch1][C][=O][N][C][C@@H1][Branch1][#C][C@H1][Branch1][O][C@@H1][Branch1][#Branch1][C@@H1][Branch1][Ring1][C][O][O][O][O][O][C][C][C@@H1][Branch1][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][O]"}, {"from": "gpt", "value": "The molecule is a derivative of the cholesterol absorption inhibitor ezetimibe designed to be non-soluble and target the luminal surface of the GI tract. In Phase II trials canosimibe reduced LDL cholesterol levels, but it did not demonstrate the desired efficacy in a Phase III study, and was discontinued."}]